List view / Grid view
Here, Chief Scientist Bruce Lahn of the CDMO VectorBuilder discusses…
Here, Chief Scientist Bruce Lahn of the CDMO VectorBuilder discusses best practices, common problems, and possible solutions to mitigate risk and free up capacity when developing and designing mRNA therapeutics.
In this in-depth focus are articles on reducing production time…
In this in-depth focus are articles on reducing production time for allogenic CAR T-cell therapies and the complexities of mRNA development, from design intricacies to scalability.
EPR Issue 4 includes articles on fridge-free vaccines, dry powder…
EPR Issue 4 includes articles on fridge-free vaccines, dry powder drug delivery, Annex 1, contamination control strategy and more.
